BCR and mantle cell lymphoma: We show that therapeutic or genetic manipulation of the BCR pathway drives biophysical changes independent of survival and cell cycle and that treatment of patients with either MCL or CLL results in rapid ex vivo changes in malignant cell mass only among responders, supporting ongoing efforts to develop cell mass as a predictive biomarker of clinical response.